

US EPA ARCHIVE DOCUMENT

FILE COPY



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

JUL 27 1994

OFFICE OF
PREVENTION, PESTICIDES AND
TOXIC SUBSTANCES

MEMORANDUM

SUBJECT: Carcinogenicity Peer Review of DIFENOCONAZOLE [DIVIDEND]

FROM: Jess Rowland, M.S., Toxicologist. *Jess Rowland 7/1/94*
Review Section IV, Toxicology Branch II
Health Effects Division (7509C)
and

Esther Rinde, Ph.D. *E. Rinde*
Manager, Carcinogenicity Peer Review Committee
Science Analysis Branch
Health Effects Division (7509C)

TO: Cynthia Giles-Parker
Product Manager #22
Fungicide/Herbicide Branch
Registration Division (7505C)

THROUGH: Penelope Fenner-Crisp, Ph.D.
Director, *PC* Health Effects Division (7509C)

The Health Effects Division Carcinogenicity Peer Review Committee (CPRC) met on May 18, 1994 to discuss and evaluate the weight-of-the-evidence on Difenconazole with particular reference to its carcinogenic potential. The CPRC concluded that Difenconazole should be classified as Group C - possible human carcinogen - and recommended that for the purpose of risk characterization, the Margin of Exposure [MOE] approach should be used for quantification of human risk.

The decision to classify Difenconazole as a Group C carcinogen was based on statistically significant increases in liver adenomas, carcinomas and combined adenomas/carcinomas in both sexes of CD-1 mice, only at doses which were considered to be excessively high for carcinogenicity testing.

The MOE approach was selected because there was only very weak (limited) evidence of carcinogenic potential at dose levels not considered to be excessive, with significant changes observed only at excessive doses. In addition, there was no evidence of genotoxicity. Therefore, a threshold model will be used for estimating risk.

Although both rats and mice showed adverse effects in the liver, the MOE will be calculated from the NOEL/LOEL established in the mouse study, since a positive (cancer) response was seen in this species. Therefore, it was determined that a no-observed-effect-level [NOEL] of 4.7 mg/kg/day and a lowest-observed-effect-level [LOEL] of 46.3 mg/kg/day will be used in the MOE calculations. The selection of a NOEL for calculating the MOE utilizes only those biological end points which are related to tumor development (non-neoplastic hepatic lesions). The endpoints considered included: liver tumors, hepatocellular hypertrophy, necrosis, fatty changes, bile stasis in mice and hepatocellular hypertrophy in the rats. In addition, these dose levels represented the majority of the NOEL's and LOEL's for the endpoints examined. Most of the other NOEL's and LOEL's were higher than the ones selected.

For comparison purposes, the NOEL selected for establishing the Reference Dose [RfD] for Difenoconazole was 0.96 mg/kg/day, based on hepatotoxicity observed in the chronic feeding study in rats. An RfD of 0.01 mg/kg/day was derived using a NOEL of 0.96 mg/kg/day and an uncertainty factor of 100 to account for inter- and intra-species variation.

SUMMARY

Administration of Difenoconazole in the diet to CD-1 mice at doses of 0, 10, 30, 300, 2500 or 4000 ppm resulted in statistically significant increases in liver adenomas, carcinomas, and adenomas/carcinomas in both sexes only at doses which the Cancer Peer Review Committee [CPRC] determined to be excessively toxic to the mice, based on liver necrosis and decreases in body weight gains. There was no apparent increase in tumors when Difenoconazole was administered in the diet to Sprague Dawley rats at doses up to and including 2500 ppm, considered to be adequate for carcinogenicity testing. Difenoconazole is a member of a class of chemicals, many of which have been associated with liver tumors in CD-1 mice. Difenoconazole does not appear to have mutagenic activity.

The Committee concluded that the top doses (2500 and 4500 ppm) were excessive in both sexes. At 4500 ppm, 9/70 males and all females died within the first two weeks of the study. Both sexes exhibited severe liver necrosis at 2500 ppm; there were also decrements in body weight gain $\geq 10\%$ at 2500 ppm at 13 weeks both in the subchronic study and in the carcinogenicity study. Weight gain decrements were greater in females; however, females did not appear to show signs of toxicity. The CPRC also determined that there was significant toxicity (including liver necrosis) at 300 ppm in the male mice; this dose also had a statistically significant increase in liver adenomas. The remaining doses (10 and 30 ppm) did not have statistically significant increases in liver tumors. The CPRC noted that there were no doses between 300 and 2500 ppm; because of the excessive toxicity at the highest doses, the CPRC concluded that this may not have been an appropriate test. [Details are provided in Section F. "The Weight of Evidence"].

The classification of Difenoconazole as a Group C Carcinogen; Possible Human Carcinogen, was based on the increased incidence of liver tumors in both sexes of mice, by both pair-wise and trend analysis. However, since the dosing was considered to be excessive, and there was no apparent genotoxicity concern, the CPRC recommended that for the purpose of risk characterization, the MOE approach should be used for quantification of human risk.

Although both rats and mice showed adverse effects in the liver, the MOE will be calculated from the NOEL/LOEL established in the mouse study, since a positive (cancer) response was seen in this species. Therefore, it was determined that a NOEL of 4.7 mg/kg/day and a LOEL of 46.3 mg/kg/day will be used in the MOE calculations. The selection of a NOEL for calculating the MOE utilizes only those biological end points which are related to tumor development (non-neoplastic hepatic lesions). The endpoints considered included: liver tumors, hepatocellular hypertrophy, necrosis, fatty changes, bile stasis in mice and hepatocellular hypertrophy in rats. In addition, these dose levels represented the majority of the NOEL's and LOEL's for the endpoints examined. Most of the other NOEL's and LOEL's were higher than the ones selected.

A. Individuals in Attendance at the meetings:

1. Peer Review Committee: (Signatures indicate concurrence with the peer review unless otherwise stated.)

Penny Fenner-Crisp	<u>Penelope A. Fenner Crisp</u>
Reto Engler	<u>Reto Engler</u>
William Burnam	<u>Wm Burnam</u>
Marcia Van Gemert	<u>Marcia Van Gemert</u>
Elizabeth Doyle	<u>Elizabeth Doyle</u>
Hugh Pettigrew	<u>Hugh Pettigrew</u>
Esther Rinde	<u>Esther Rinde</u>
Yin Tak Woo	<u>Yin Tak Woo</u>

2. Reviewers: (Non-committee members responsible for data presentation; signatures indicate technical accuracy of panel report.)

Jess Rowland ¹	<u>Jess Rowland</u>
Clark Swentzel	<u>Clark Swentzel</u>
Lori Brunzman	<u>Lori S. Brunzman</u>
Bernice Fisher	<u>Bernice Fisher</u>
Lucas Brennecke ² (PAI/Clement)	<u>Lucas W. Brennecke</u>

3. Other Attendees

Bernice Fisher (HED)

¹Also a member of the PRC for this chemical; signature indicates concurrence with the peer review unless otherwise stated.


²Signature indicates concurrence with pathology report.

B. Materials Reviewed:

The material available for review consisted of Data Evaluation Records and other data summaries prepared by Jess Rowland, and statistical analyses prepared by Lori Brunsmann. Also included was a Position Document entitled: "Assessment of the Liver Tumors Observed in CD-1 Mice Fed Excessive Levels of Difenoconazole [CGA 169374]: A Mitogenic Response". Submitted by the Registrant, Ciba-Geigy Corporation. The material reviewed is attached to the file copy of this report. Studies were submitted by Ciba-Geigy Corporation.

C. Background Information

Difenoconazole [CGA-169374 Technical]; 1-[2-(2-chloro-4-(4-chlorophenoxy)phenyl)-4-methyl-1,3-dioxolan-2-yl]-methyl-1H-1,2,4-triazole] is a triazole fungicide. The P.C Code is 128847 and the Caswell Number is 955. The Registrant, Ciba-Geigy, is requesting tolerances allowing import of wheat, barley, and rye grain harvested from Difenoconazole treated seed as well as domestic tolerances of this fungicide in straw and forage of wheat and barley. The structure of Difenoconazole is provided below:



D. Evaluation of the carcinogenic potential

1. Carcinogenicity Study in Mice:

Reference: Cox, R.H. Oncogenicity Study in Mice. Project Report 483-250. Hazleton Laboratories, Report issued, April 3, 1989. MRID # 420900-15 & 427100-06. HED Document # 009689 & 010588

a. Experimental Design

Groups of 60-70 male and 60-70 female Crl:CD-1 mice were fed diets containing difenoconazole at 0, 10, 30, 300, 2500 or 4500 ppm [males only] for 78 weeks. The mean daily test article intake was 1.5, 5, 46, 423 and 819 mg/kg/day in males and 2, 6, 58 and 512 mg/kg/day in females, respectively. Ten animals per sex from each group were sacrificed after 52 weeks of treatment. Ten additional animals, allocated to the control, 2500 ppm and 4500 ppm dose groups were kept for a four week recovery period after one year on the study.

b. Discussion of Tumor Data

As shown in Table 1, male mice exhibited significant [$p < 0.01$] increasing trends in hepatocellular adenomas, carcinomas, and combined adenomas/carcinomas. Pair-wise comparison showed a significant [$p < 0.05$] increase in hepatocellular adenomas at 300 ppm [9/56, 16%] when compared to controls [4/68, 6%]. Pair-wise comparison showed significant [$p < 0.05$] increases in hepatocellular adenomas [13/70, 19%] and adenomas/carcinomas combined [16/70, 23%] at 2500 ppm when compared to controls [adenomas: 4/68, 6%; adenomas/ carcinomas combined, 5/68, 7%]. Pair-wise comparison showed significant [$p < 0.01$] increases in adenomas [20/56, 36%], carcinomas [13/56, 23%] and adenomas/ carcinomas combined [28/56, 50%] at 4500 ppm when compared to controls [adenomas: 4/68, 6%; carcinomas, 1/68, 1%; and adenomas/carcinomas combined, 5/68, 7%].

As shown in Table 2, female mice exhibited significant [$p < 0.01$] dose-related increasing trends in hepatocellular adenomas, carcinomas, and adenomas/carcinomas combined. Pair-wise comparison showed a significant increase in hepatocellular adenomas at 2500 ppm [16/59, 27%; $p < 0.01$], carcinomas [4/39, 10%; $p < 0.05$], and adenomas/ carcinomas combined [17/59, 29%; $p < 0.01$] when compared to none of each in the controls.

Table 1. Hepatocellular Tumor Rates⁺ and Peto's Prevalence Test Results in MALE MICE

ppm	0	10	30	300	2500	4500
mg/kg/day	0	1.51	4.65	46.29	423.16	818.87
Adenomas	4/68	10/57	8/58	9/56	13 ^a /70	20/56
%	6	18	14	16	19	36
p =	0.000 ^{**}	0.053	0.078	0.035 [*]	0.036 [*]	0.000 ^{**}
Carcinomas	1/68	0/57	1/58	0/56	5/70	13 ^b /56
%	1	0	2	0	7	23
p =	0.000 ^{**}	--	0.546	--	0.093	0.000 ^{**}
Combined	5/68	10/57	9/58	9/56	16 ^c /70	28 ^c /56
%	7	18	16	16	23	50
p =	0.000 ^{**}	0.114	0.128	0.061	0.023 [*]	0.000 ^{**}

⁺ No. of tumor bearing animals / No. of animals examined [excluding those that died or were sacrificed before observation of first tumor.

^a First adenoma observed at week 53, dose 2500 ppm.

^b First carcinoma observed at week 53, dose 4500 ppm.

^c Includes animals with more than one tumor type [i.e., adenomas + carcinomas]

Note: Significance of trend denoted at control.

Significance of pair-wise comparison with control denoted at dose level.

If ^{*}, then $p < 0.05$. If ^{**}, then $p < 0.01$.

Table 2. Hepatocellular Tumor Rates⁺/Exact Trend Test/Fisher's Exact Test Results in FEMALE MICE

ppm	0	10	30	300	2500
mg/kg/day	0	1.90	5.63	57.79	512.61
Adenomas	0/57	0/56	0/56	1/56	16 ^a /59
%	0	0	0	2	27
p =	0.000 ^{**}	1.000	1.000	0.496	0.000 ^{**}
Carcinomas	0/47	0/45	1/44	0/45	4 ^b /39
%	0	0	2	0	10
p =	0.002 ^{**}	1.000	0.484	1.000	0.039 [*]
Combined	0/57	0/56	1/56	1/56	17 ^c /59
%	0	0	2	2	29
p =	0.000 ^{**}	1.000	0.496	0.496	0.000 [*]

⁺ No. of tumor bearing animals / No. of animals examined [excluding those that died or were sacrificed before observation of first tumors, Week 53 for adenomas and combined, and Week 58 for carcinomas].

^a First adenoma observed at week 53, dose 2500 ppm.

^b First carcinoma observed at week 72, dose 2500 ppm.

^c Includes animals with more than one tumor type [i.e., adenomas + carcinomas]

Note: Significance of trend denoted at control.

Significance of pair-wise comparison with control denoted at dose level.

If ^{*}, then p < 0.05. If ^{**}, then p < 0.01.

Historical control data for hepatocellular adenomas and carcinomas observed in Charles River CD-1 mice from 10 studies conducted at the testing laboratory [Hazleton Labs] are presented in Table 3. Historical control data were not available for combined adenomas/carcinomas.

In males, the incidence of hepatocellular adenomas at 300 ppm [9/56, 16%], at 2500 ppm [13/70, 19%] and at 4500 ppm [20/56, 36%] exceeded both the weighted average of the historical control incidences [7.4%] from all studies and the historical control range [2 - 11%]. Hepatocellular carcinomas [13/56; 23%] at the 4500 ppm also exceeded the weighted average of the historical control incidences [3%] from all studies and the historical control range [0 - 8.2%]. The incidence of hepatocellular adenomas and carcinomas in the concurrent untreated males was 6% and 1%, respectively.

In females, the incidence of hepatocellular adenomas [16/59; 27%] at 2500 ppm [HDT] also exceeded the weighted average of the historical control incidences [1.4%] from all studies and the historical control range [0 - 6.1%]. Hepatocellular carcinomas [4/39; 10%] at the HDT exceeded both the weighted average of the historical control incidences [0.6%] from all studies and the historical control range [0 - 2.1%]. No liver tumors were seen in the concurrent untreated females.

Table 3. Historical Control: Hepatocellular Adenomas and Carcinomas in CD-1 Mice*

Study Identification	Adenomas [%]	Carcinomas [%]
MALES		
5DE	4/51 [7.8]	1/51 [2.0]
6DE	2/49 [4.1]	2/49 [4.1]
1DE	1/49 [2.0]	4/49 [8.2]
2DE	4/49 [8.2]	1/49 [2.0]
10DE	6/55 [11.0]	3/55 [5.5]
7DE	3/47 [6.4]	0/47 [0.0]
11DE	4/50 [8.0]	0/50 [0.0]
8DE	5/50 [10.0]	1/50 [2.0]
4DE	4/50 [8.0]	2/50 4.0]
26DE	4/49 [8.2]	1/49 2.0]
Weighted Average	[7.4]	[3.0]
FEMALES		
5DE	0/40 [0.0]	0/49 [0.0]
6DE	0/48 [0.0]	1/48 [2.1]
1DE	1/48 [2.1]	0/48 [0.0]
2DE	3/49 [6.1]	0/49 [0.0]
10DE	0/55 [0.0]	0/55 [0.0]
7DE	1/49 [2.0]	1/49 [2.0]
11DE	0/50 [0.0]	0/50 [0.0]
8DE	0/49 [0.0]	0/49 [0.0]
4DE	1/50 [2.0]	0/50 [0.0]
26DE	1/48 [2.1]	1/48 [2.1]
Weighted Average	[1.4]	[0.6]

* Historical control data were obtained from 10 chronic/carcinogenicity studies with Charles River CD-1 mice conducted at Hazleton Laboratories between April 1984 and April 1987. All studies were 78 weeks in duration.

Treatment-related non-neoplastic histopathological changes were confined to the liver and included: necrosis of individual hepatocytes; focal/multifocal necrosis; hepatocellular hypertrophy; inflammation; bile stasis; and fatty changes. These lesions were observed at the interim and terminal sacrifices in males at 300 ppm and above and in the females at 300 and 2500 ppm. Hepatic lesions are summarized below in Table 4.

Table 4. Non-Neoplastic Lesions in the Liver of Mice fed Difenconazole.

Hepatic Lesions	0 ppm		10 ppm		30 ppm		300 ppm		2500 ppm		4500 ppm	
Sex No. Examined	M 70	F 60	M 60	F 60	M 60	F 60	M 70	F 70	M 70	F 70	M 70	F #
Necrosis of individual hepatocytes	5	3	5	0	2	0	13 *	6	52 **	27 **	53 **	
Focal/multifocal necrosis	4	4	2	2	4	0	6	7	11 *	6	16 **	
Hypertrophy	17	2	16	7	15	2	26 *	7	61 **	53 **	57 **	
Inflammation	18	13	5	13	8	7	12	18	21	12	7	
Bile stasis	1	0	0	0	0	0	3	3	56 **	50 **	50 **	
Fatty changes	2	0	1	0	0	2	4	2	13 **	9 **	32 **	

Females were not dosed at this level.

* = $P \leq 0.05$; ** = $P \leq 0.01$; significantly different from the controls.

d. Toxicological Effects

The statistical evaluation of mortality indicated a significant increasing trend in mortality with increasing doses of Difenconazole in male mice. Females showed no significant incremental changes in mortality with increasing doses of the test compound. At 4500 ppm, 9/70 males and all females died within the first two weeks of the study. Prior to death, clinical signs of toxicity included thinness, hunched posture and rough haircoat in the high-dose females. These signs were also seen with increased incidence throughout the study in both sexes at 2500 ppm and in the remaining males at 4500 ppm. In spite of comparable food consumption, cumulative body weight in at 13 weeks was approximately 16%, 19% and 64% lower [statistically significant at $p < 0.05$] than the weight gain of the control males at 300, 2500 and 4500 ppm, respectively. At termination, the values for male mice were 12%, 10% and 34% at 300, 2500 and 4500 ppm, respectively. In females, at 13 weeks, reductions in body weight gain were 16% at 300 ppm and 33% at 2500 ppm. At termination, the values were 7% at 300 ppm and 22% at 2500 ppm. Alterations in clinical chemistry were manifested by elevations in alanine aminotransferase, SAP and SDH in males at 2500 and 4500 ppm and in females at 2500 ppm.

e. Adequacy of Dosing for Assessment of Carcinogenic Potential

The highest dose tested [2500 ppm in females and 4500 ppm in males] induced toxicological [mortality, \geq 10% reductions in body weight gains and clinical signs], pharmacological [changes in liver enzymes indicative of liver damage], and histopathological [non-neoplastic and neoplastic hepatic lesions] changes in both sexes of mice. However, this dose appears to be excessively high for carcinogenicity testing due to severe body weight decreases and liver necrosis in both sexes, and that the 4500 ppm dose tested in female mice was excessive due to the high mortality rate. The 300 ppm dose was considered adequate for assessing carcinogenicity in males, but not in females.

2. Chronic Toxicity/Carcinogenicity Study in Rats:

Reference: Cox, R.H. Combined Chronic Toxicity and Oncogenicity Study of CGA 169374 Technical in Rats. Project Report 483-249. Hazleton Laboratories, Report issued, March 31, 1989. MRID # 420900-19 & 427100-10. HED Document # 009689 & 010588.

a. Experimental Design

Groups of 80 male and 80 female Sprague-Dawley rats were fed diets containing Difenoconazole at 0, 10, 20, 500 or 2500 ppm for 104 weeks. The mean daily test article intake was 0.48, 0.96, 24.1 and 124 mg/kg/day in males and 0.64, 1.27, 32.8 and 170 mg/kg/day in females, respectively. Ten animals per sex from each group and were sacrificed after 52 weeks of treatment. Ten additional animals, allocated to the control and 2500 ppm dose groups were kept for a four weeks recovery period after one year on the study.

b. Discussion of Tumor Data

Difenoconazole did not increase the neoplastic lesions commonly seen in this strain/age of rats. Statistical analyses of tumor data showed no significant treatment-related or dose-related tumors in either sex of rats.

c. Non-neoplastic Lesions

As shown in Table 5, treatment-related non-neoplastic histopathological changes were limited to an increased incidence of hepatocytic hypertrophy [centrilobular to diffuse to focal/multifocal] in both sexes at 500 and 2500 ppm. The lesions were characterized by the presence of lightly stained enlarged hepatocytes with poorly distinguishable cell borders.

Table 5. Non-Neoplastic Lesions in the Liver of Rats fed Difenoconazole.

Hepatic Lesions	0 ppm		10 ppm		20 ppm		500 ppm		2500 ppm	
No. Examined: 70/Dose	M	F	M	F	M	F	M	F	M	F
Hepatocytic # hypertrophy [%]	7 [10]	4 [6]	5 [7]	0 [0]	8 [11]	0 [0]	29 [41]	17 [24]	39 [56]	36 [51]

d. Toxicological Effects

Treatment caused no adverse effect on survival. Over the first year of treatment, body weight gain of the 500 and 2500 ppm groups was 94% and 80% of the control values in males and 90% and 59% in the females [statistical significance at $p < 0.05$], respectively. The mean body weights of the rats at 2500 ppm remained consistently below the control values reaching 89% of the control values in the males and 63% in the females, respectively at termination. The only remarkable changes seen in clinical chemistry parameters were consistently [at Weeks 28, 53, 79 and 105] increased albumin and decreased globulin concentrations in the males at 2500 ppm which resulted in an increased albumin/globulin ratio. At both the interim and terminal sacrifices, absolute and relative liver weights were elevated at 2500 ppm. After 52 weeks of treatment, the liver-to-body weight ratio amounted to 114% of the control value in males and 148% in females, respectively. The values were in the same range at terminal sacrifice.

e. Adequacy of Dosing for Assessment of Carcinogenic Potential

The highest dose tested [2500 ppm] induced toxicological [$\geq 10\%$ reductions in body weight/body weight gain], pharmacological [liver effects indicative of enhanced functional load], and histopathological [non-neoplastic hepatic lesions] changes. Therefore, it is concluded that the dose levels employed in this study were adequate to assess the chronic toxicity and the carcinogenicity potential of Difenoconazole in rats.

E. Additional Toxicology Data on Difenoconazole

1. Metabolism

Reference: Absorption, Distribution and Metabolism Studies in Rats with Difenoconazole.
MRID # 420900-28/29/30/31; 427100-13/14; HED Document # 009689 & 010588

The biotransformation of Difenoconazole is shown in Figure 1. The compound undergoes successive oxidation and conjugation reactions. One of its metabolites, CGA-205375, accounts for 6-24% of the applied dose and is found only in urine and feces of oral high-dose (300 mg/kg) rats. The presence of this intermediate in excreta of only high-dose rats, suggests that its rate of further biotransformation has reached saturation at the high dose. Additionally, excretion of radioactivity in bile, feces and urine of rats orally dosed with [^{14}C]-difenoconazole is consistent with saturation g.i. absorption of the chemical at 300 mg/kg.

2. Mutagenicity

Reference: Mutagenicity Studies with Difenoconazole.

MRID # 420900-25; 427100-11 & 427100-12 HED Document # 09689 & 010588

Difenoconazole was nonmutagenic with or without metabolic activation, when tested at concentrations ranging from 340 to 5447 µg/plate in two independently performed microbial/mammalian microsome plate incorporation assays using *Salmonella typhimurium* strains TA1535, TA1537, TA98 and TA100 and *Escherichia coli* strain WP2uvrA. In an *in vivo*, micronucleus assay, no increase in micronucleated polychromatic erythrocyte counts were seen in the bone marrow cells of mice given oral administration of difenoconazole at 0, 400, 800 or 1600 mg/kg/day. Difenoconazole was negative in an *in vitro* UDS assay with primary rat hepatocytes at concentrations up to 50.0 µg/mL.

3. Subchronic and Chronic Toxicity

Reference: 13-Week Feeding Study in Mice. MRID# 420900-21; HED Document # 009689

In a subchronic toxicity study CD-1 mice [15/sex/dose] were fed diets containing Difenoconazole at 0, 20, 200, 2500, 7500 or 15,000 ppm for 13 weeks. These levels were equivalent to approximately 0, 3, 30, 375, 1125 or 2250 mg/kg/day, respectively. All but 2 mice fed 7500 ppm and all mice fed 15,000 ppm died during the first three weeks of the study. Clinical signs seen prior to death were thinness, hunched posture, languidness and tremors. At 2500 ppm, the cumulative body weight gains were decreased by 9% for males and 41% for females and the absolute and relative liver weights were significantly increased in both sexes. Histopathology revealed erosion/ulceration of the glandular stomach and hyperkeratosis of the non-glandular stomach as well as diffused hepatocellular enlargement and necrosis in many of the mice that died. Histopathology showed hypertrophic and cytotoxic changes in the liver at feeding levels \geq 2500 ppm; hepatocellular enlargement was seen in all mice [10/sex] while vacuolation was seen in 7 males and 7 females at 2500 ppm. Results indicate that the MTD is lower than 2500 ppm. A LOEL of 200 ppm [30 mg/kg/day] was based on mortality, reductions in body weight gain, and histopathologic alterations in the liver. The NOEL was 20 ppm [3 mg/kg/day].

Reference: 13-Week Feeding Study in Rats; MRID # 420900-22; HED Document # 009689

In a subchronic toxicity study Sprague-Dawley rats [15/sex/dose] were fed diets containing Difenoconazole at 0, 20, 200, 750, 1500 or 3000 ppm for 13 weeks. These levels were equivalent to 0, 1.23, 11.3, 47.8, 99.3, and 189 mg/kg/day in males and 0, 1.43, 15.5, 61.8, 124 and 194 mg/kg/day in females, respectively. The body weight gains were significantly reduced in males at 3000 ppm and in females at 200 ppm and above. At the high dose, the overall body weight gain amounted to 85% of the control value in males and 62% in females, respectively. The absolute and relative liver weights were significantly increased in males at 750 and above and in females at 200 ppm and above.

Although no changes in key liver marker enzymes were observed, histopathology revealed a dose-related increased incidence of diffuse hepatocellular enlargement in both sexes treated at 1500 ppm and above. Results indicate that the MTD was exceeded at 3000 ppm due to severe depression in body weight gain. A LOEL of 200 ppm [11.3 mg/kg/day in males and 15.5 mg/kg/day in females] was based on reductions in body weight gain and increased liver weights. The NOEL was 20 ppm [1.23 mg/kg/day in males and 1.43 mg/kg/day in females].

Reference: 52-Week Feeding Study in Dogs.

MRID #420900-14 & 427100-05

HED Document # 009689 & 010588

In a chronic toxicity study, beagle dogs [4/sex/dose] were fed diets containing Difenoconazole at 0, 20, 100, 500 or 1500 ppm for 52 weeks. These levels were equivalent to 0, 0.71, 3.4, 16.4 or 51.2 mg/kg/day in males and 0, 0.63, 3.7, 19.4 or 44.3 mg/kg/day in females, respectively. The body weight gain was consistently diminished in females at 500 and 1500 ppm; at termination the body weight gain was 60% and 69% of the control values, respectively. No reductions in body weight gain were seen in male dogs at any dose level. Male dogs exhibited dose-related increases in serum alkaline phosphatase activity on Days 85, 175 and 359 with the increase reaching statistical significance at the high dose. No treatment-related histopathologic changes were seen. A LOEL of 500 ppm [16.4 mg/kg/day in males and 19.4 mg/kg/day in females] was based on reductions in body weight gain. The NOEL is 100 ppm [3.4 mg/kg/day in males and 3.7 mg/kg/day in females]

Reference: 78-Week Feeding Study in Mice.

MRID # 420900-15 & 427100-06.

HED Document # 009689 & 010588

In a carcinogenicity study [discussed in detail on Page 5], CD-1 mice [60-70/sex/dose] were fed diets containing Difenoconazole at 0, 10, 30, 300, 2500 or 4500 ppm [males only] for 78 weeks. The systemic LOEL of 300 ppm [46.29 mg/kg/day in males and 57.79 mg/kg/day in females] was based on reductions in cumulative body weight gain. The NOEL was 30 ppm [4.65 mg/kg/day in males and 5.63 mg/kg/day in females].

Reference: 104-Week Feeding Study in Rats.

MRID # 420900-15 & 427100-06.

HED Document # 009689 & 010588

In a chronic toxicity/carcinogenicity study [discussed in detail on Page 10], Sprague-Dawley rats were fed diets containing difenoconazole at 0, 10, 20, 500 or 2500 ppm for 104 weeks. The systemic LOEL of 500 ppm [24.12 mg/kg/day in males and 32.79 mg/kg/day in females] was based on reductions in cumulative body weight gain. The NOEL was 20 ppm [0.96 mg/kg/day in males and 1.27 mg/kg/day in females].

4. Registrant's Rebuttal Concerning Carcinogenicity of Difenoconazole in Mice.

Reference: Position Document entitled: "Assessment of the Liver Tumors Observed in CD-1 Mice Fed Excessive Levels of Difenoconazole [CGA 169374]: A Mitogenic Response". Submitted by Ciba-Geigy Corporation. MRID # 429728-03

The Registrant contends that the carcinogenic response was noted 1) at excessive dietary levels where the hepatocytotoxic maximum tolerated dose was exceeded; 2) liver tumors were accompanied by a clear sequela of non-neoplastic changes which clearly support a hepatotrophic effect; and 3) liver damage is most likely to result in mitogenesis [cell replication] in the liver. The Registrant, therefore, asserts that the liver tumors observed in the mouse study are not germane to the toxicological assessment of human exposure to difenoconazole.

The CPRC considered the tumors in the mice along with the ancillary data to constitute limited evidence of carcinogenicity. The CPRC agreed that the tumors in the mice occurred only at doses which were excessively toxic, and concluded that the mouse study may not have been an appropriate test. The 300 ppm dose was considered adequate for assessing carcinogenicity in males, but not in females; it was also noted that there were no doses between 300 ppm and 2500 ppm.

5. Structure-Activity Relationships

Difenoconazole is structurally related to Azaconazole, Baycor, Bayleton, Baytan, Cyproconazole, Etaconazole, Fenbuconazole, Hexaconazole, Propiconazole, Tebuconazole, and Uniconazole. The structural formulas of these compounds are shown in Table 6. The tumor types and cancer classifications of these compounds are provided below:

Azaconazole: Non carcinogenic in male and female mice [strain not specified]; the doses used may not have been adequate to assess the carcinogenic potential of this compound.

Baycor: Non carcinogenic in male and female mice and male and female rats at doses up to and including 500 ppm.

Bayleton: Group "C" (No Q) carcinogen; based on hepatocellular adenomas in male and female NMRI mice and a dose-related trend for thyroid follicular cell adenomas in males and cystic hyperplasia in both sexes.

Baytan: "Weak C" carcinogen; based on hepatocellular adenomas and hyperplastic nodules in female CF1-W74 mice.

Cyproconazole: Group B2 carcinogen; based on hepatocellular adenomas and carcinomas in male and female CD-1 mice and the absence of an acceptable carcinogenicity study in rats.

Etaconazole: No classification; increased the incidence of liver adenomas and carcinomas; registration voluntarily withdrawn.

Fenbuconazole: Group C (Q) carcinogen; based on thyroid follicular cell adenomas and/or combined adenomas/carcinomas in male Sprague-Dawley rats in two studies. Increased incidence of hepatocellular adenomas and/or carcinomas in CD-1 mice fed inadequate doses.

Hexaconazole: Group C (Q) carcinogen; based on benign Leydig cell testicular tumors in ALpk:APfSD (Wistar derived) rats. Doses used in the CD-1/Alpk mouse study were not adequate to assess carcinogenicity.

Propiconazole: Group C (No Q) carcinogen; based on hepatocellular adenomas, carcinomas, and/or adenomas and carcinomas combined in CD-1 mice.

Tebuconazole: Group C (No Q) carcinogen; based on hepatocellular adenomas, carcinomas, and combined adenomas/carcinomas in both sexes of NMRI mice.

Uniconazole: Group C (No Q) carcinogen; based on hepatocellular adenomas and carcinomas in male Crl:CD-1(ICR)BR mice. Non carcinogenic in male or female rats.

F. Weight of Evidence Considerations

The Committee considered the following observations regarding the toxicology of Difenoconazole for a weight-of-the-evidence determination on its carcinogenic potential:

1. Male and female CD-1 mice were fed diets containing Difenoconazole at 0, 10, 30, 300, 2500 or 4500 ppm for 78 weeks. The highest dose tested, 4500 ppm was determined to be excessively high for carcinogenicity testing due to high mortality where 11/70 males and all females died within the first two weeks of the study. The next lower dose, 2500 ppm, was also determined to be too high for carcinogenicity testing due to severe reductions [statistically significant] in body weight gain by week 13 in both sexes. At 13 weeks, treated males and females exhibited a 16% and 33%, respectively, lower body weight gain compared to that of the weight gain of the control animals. In addition, histopathology revealed statistically increased incidences of liver necrosis in both sexes of mice at this dose. Because of the excessive dosing in this study, the relevance to carcinogenicity in humans of the tumors occurring at these doses [2500 and 4500 ppm] was questioned by the Committee. The next lower dose [300 ppm] was considered to be an adequate dose to assess carcinogenicity in male mice but not in female mice. This was based on the fact that while males exhibited body weight loss as well as liver necrosis, females exhibited only body weight loss without any other toxicological effects.

In male mice, there was a significant [$p=0.000$] increasing trend in hepatocellular adenomas, carcinomas, and combined adenomas/carcinomas. At 300 ppm, hepatocellular adenomas [16%] were significantly [$p=0.035$] increased when compared to controls [6%]. At 2500 ppm, hepatocellular adenomas [19%; $p=0.036$] and combined adenomas/carcinomas [23%; $p=0.023$] were significantly increased when compared to controls [adenomas: 6%; combined adenomas/carcinomas: 7%]. At 4500 ppm, adenomas [36%], carcinomas [23%] and combined adenomas/carcinomas [50%] were significantly [$p < 0.000$] increased when compared to controls [adenomas: 6%; carcinomas: 1%; and combined adenomas/carcinomas: 7%]. In addition, there was a statistically significant positive trend [$p = 0.000$] for adenomas, carcinomas, and adenomas/carcinomas.

In female mice, there was a significant [$p < 0.01$] dose-related increasing trend in hepatocellular adenomas, carcinomas, and combined adenomas/carcinomas. At 2500 ppm, hepatocellular adenomas [27%; $p=0.000$], carcinomas [10%; $p=0.039$], and combined adenomas/carcinomas [29%; $p=0.000$] when compared to none in the controls. In addition, there was a statistically significant positive trend [$p = 0.000$] for adenomas, carcinomas, and adenomas/carcinomas.

When compared to historical control data, in male mice, the dose-related increases in the incidence of hepatocellular adenomas [16% at 300 ppm, 19% at 2500 ppm and 36% at 4500 ppm] exceeded the concurrent controls [6%] as well as both the weighted average of the historical control incidence [7.4%] and the historical control range [0 - 11%]. Similarly, hepatocellular carcinomas [10%] at the HDT also exceeded the concurrent controls [1%] as well as the weighted average of the historical control incidence [3%] and the historical control range [0 - 8.2%].

When compared to historical control data, in female mice, the incidence of hepatocellular adenomas [27%] at the HDT exceeded the concurrent controls [0%] and the weighted average of the historical control incidence [1.4%] and the historical control range [0 - 6.1%]. Similarly, hepatocellular carcinomas [29%] at the HDT exceeded the concurrent controls [0%] and both the weighted average of the historical control incidence [0.6%] and the historical control range [0 - 2.1%].

2. Difenoconazole has been shown to be nonmutagenic both *in vivo* and *in vitro*. It was negative for gene mutations in a *Salmonella*/microsomal assay, did not cause an increase in micronucleated polychromatic erythrocytes in a mouse micronucleus assay, and was negative in an UDS assay with primary rat hepatocytes.
3. Difenoconazole is structurally related to other triazole pesticides such as Cyproconazole, Fenbuconazole, Propiconazole, Tebuconazole, and Uniconazole] known to have induced hepatocellular adenomas, carcinomas, and/or adenomas and carcinomas combined in several strains [CD-1, Swiss, NMRI, and CF1-W74] mice. An other analog, Bayleton, induced thyroid follicular tumors in rats.

4. Carcinogenicity in animals -- Difenconazole

After a full evaluation of all of the data and supporting information regarding animal carcinogenicity, the Committee concludes that exposure to Difenconazole resulted in an increased incidence of adenomas, malignant carcinomas and combined adenomas/carcinomas in both sexes of CD-1 mice. Difenconazole is a member of a class of compounds, many of which have been associated with liver tumors in mice. The relevance of the tumor data to an evaluation of Difenconazole's potential for human carcinogenicity is discussed elsewhere in this report.

G. Classification of Carcinogenic Potential:

The CPMC considered the criteria contained in the EPA's "Guidelines for Carcinogenic Risk Assessment" [FR51: 33992-34003, 1986] for classifying the Weight of the Evidence for carcinogenicity of Difenconazole.

The CPMC agreed that there was limited evidence for carcinogenicity and that Difenconazole should be classified as a Group C - possible human carcinogen, and that for the purpose of risk characterization the Margin of Exposure [MOE] approach should be used for quantification of human risk.

The decision to classify Difenconazole as a Group C carcinogen was based on statistically significant increases in hepatocellular adenomas, carcinomas and combined adenomas/carcinomas in both sexes of CD-1 mice, which occurred only at doses considered to be excessively high for carcinogenicity testing. There were no apparent tumor increases in either sex in Sprague-Dawley rats at dietary levels up to 2500 ppm and Difenconazole does not appear to have mutagenic activity. Difenconazole is a member of a class of chemicals, many of which have been associated with liver tumors in CD-1 mice.

The CPMC concluded that the mouse study may not have been an appropriate test, due to the excessive toxicity in both sexes at the two top doses [2500 and 4500 ppm]; there were also no doses between 300 and 2500 ppm. The 300 ppm dose was considered adequate for assessing carcinogenicity in males, but not in females.

Based on the CPMC's recommendation of using the MOE approach for risk characterization, MOEs will be calculated to estimate the risk from exposure to Difenconazole.

The selection of a NOEL for calculating MOE utilizes only those biological endpoints which are related to tumor development.

Presented below are the endpoints, NOELs and LOELs considered by the CPRC in selecting a NOEL used in the calculations of MOEs for evaluating the potential carcinogenic risk of Difenconazole:

Type of Study	Endpoint	NOEL [mg/kg/day]		LOEL [mg/kg/day]	
		Males	Female	Males	Females
18-Month Feeding-Mouse	Hepatocellular Adenomas	4.7	57.8	46.3	512.6
	Hepatocellular Carcinomas	423.2	57.8	818.9	512.6
	Hepatocellular Adenomas/Carcinomas	46.3	57.8	423.2	512.6
	Necrosis of Individual Hepatocytes	4.7	57.8	46.3	512.6
	Liver-Focal/multifocal Necrosis	46.3	512.6	423.2	— ^a
	Hepatocellular hypertrophy	4.7	57.8	46.3	512.6
	Bile stasis	46.3	57.8	423.2	512.6
	Fatty Changes of the liver	46.3	57.8	423.2	512.6
2-Year Feeding- Rat	Hepatocellular hypertrophy	0.96	1.27	24.1	32.8
	Increase in Liver Weights	24.1	32.8	124.0	170.0
	Increase in Albumin/Globulin Ratio	24.1	— ^a	124.0	— ^a
1-Year Feeding-Dog	Decreases in Body Weight Gain	3.4	3.7	16.4	19.4

a = Effects were not seen in females to establish a NOEL/LOEL

The liver was the target organ in both sexes of mice and rats. Although non-neoplastic lesions were seen in both species, liver tumors were seen only in mice. Non-neoplastic lesions observed in both sexes of mice were hepatocellular hypertrophy, necrosis, fatty changes, and bile stasis. These lesions were observed with increasing incidence and severity in mice at 300 ppm [46.3 mg/kg/day] and above. Hepatotoxicity in rats manifested as hepatocellular hypertrophy at 500 ppm [24.1 mg/kg/day] and 2500 ppm [32.8 mg/kg/day], increases in both absolute and relative liver weights, and albumin/globulin ratios at 2500 ppm.

A NOEL of [30 ppm] 4.7 mg/kg/day and a LOEL of 300 ppm [46.3 mg/kg/day] were selected for MOE calculations. The LOEL is based on the hepatocellular adenomas, necrosis of the individual hepatocytes, and hepatocellular hypertrophy observed in male mice. The only other endpoint that had a lower NOEL than the 4.7 mg/kg/day was the hepatocellular hypertrophy observed in both sexes of rats. The NOELs for this endpoint were 0.96 mg/kg/day in males and 1.27 mg/kg/day in females; the LOELs were 24.1 mg/kg/day and 32.8 mg/kg/day.

For comparison purposes, the NOEL selected for establishing the Reference Dose [RfD] for Difenconazole was 0.96 mg/kg/day, based on hepatotoxicity observed in the chronic feeding study in rats. An RfD of 0.01 mg/kg/day was derived using a NOEL of 0.96 mg/kg/day and an uncertainty factor of 100 to account for inter- and intra-species variation.

Table 6. Structurally Related Triazole Pesticides.




Compound	Structure	Carcinogenic Effect	Carcinogen Classification
Bayleton PC Code 109901 Tox. Chem. # 862AA		NMRI Mouse, 50, 300, & 1800 ppm. Only hepatocellular adenoma, at 1800 ppm in (22%) ♂ & (18%) ♀, $p < 0.05$ for trend and paired comparisons. Hist. Conts.: 18.4% ♂ & 2.0% ♀. Wistar Rat, 50, 500 & 5000 ppm. Dose related trend in TFC adenomas in ♂ & comb. w. cystic hyperplasia in ♂ & ♀; pairwise comparisons not significant.	CNQ
Baytan PC Code: 127201 Tox. Chem # 074A		CF1-W74 Mouse, 2000 ppm: Hepatocellular adenomas and hyperplastic nodules ($p < 0.01$) in ♀. No increase in ♂. Adrenal adenomas noted in ♀ LDT and HDT but not in hist. conts. No elevation in carcinomas.	Weak C SAP 12/23/87.
Baycor PC Code: 112403 Tox Chem.# 087AA		Mouse: up to 500 ppm: (-) Rat: up to 500 ppm : (-)	

Table 6. Structurally Related Triazole Pesticides (Continued)




Compound	Structure	Carcinogenic Effect	Carcinogen Classification
Propiconazole PC Code: 122101 Tox. Chem. # 323EE		CD-1 Mouse, 100, 500 & 2500 ppm. Statistically significant trend and pairwise comparisons in liver adenomas and combined at 2500 ppm. For carcinomas only there were statistically significant trend and pairwise comparisons at the HDT for data from 2 of 3 pathologists; for the data from the third pathologist only the trend was significant ($p=0.028$), the pairwise comparison HDT vs. control had a $p = 0.050$.	CNQ
Etaconazole PC: None		Swiss Mouse increased incidence of liver adenomas and carcinomas in both sexes. Registration voluntarily withdrawn.	None
Azaconazole PC Code: 128882 Tox. Chem. # 321A		Mouse, 25,100 & 400 ppm. There is the question of whether the MTD was reached. No carcinogenicity effect.	

Table 6. Structurally Related Triazole Pesticides (Continued).






Compound	Structure	Carcinogenic Effect	Carcinogen Classification
Hexaconazole PC Code: 128925 Tox. Chem. # 480G		CD-1/Alpk Mouse, 5, 40 & 200 ppm. No carcinogenicity effect. Should be evaluated with caution since an MTD was not reached. ALpk:APfSD (Wistar derived) Rats, 10, 100, 1000 ppm. There was a significant ($p < 0.01$) dose-related trend and a significant pair-wise comparison with controls at the HDT for benign Leydig cell tumors in the testes. The incidence at HDT (16%) exceeded historical control values of up to 6.0%	C Q (Based on rat Study)
Cyproconazole PC Code: 128993 Tox. Chem. # 272E		CD-1 Mouse, 5, 15, 100 & 200 ppm. Significant incidence of adenomas & carcinomas at the MDT and HDT in males and at the HDT in females.	B2
Uniconazole PC Code: 128976 Tox. Chem. # 207H		Crl:CD-1(ICR)BR Mouse, 10, 40, 200 & 1500 ppm. Increased incidence of hepatocellular adenomas & carcinomas in 1500 ppm males only. Crl:CD-1(ICR)SD Rat, 10, 40 200 & 1000 ppm. No increase in neoplastic findings.	C NQ

Table 6. Structurally Related Triazole Pesticides (Continued).

Compound	Structure	Carcinogenic Effect	Carcinogen Classification
Tebuconazole PC Code: Tox. Chem. # 463P		NMRI Mice, 0, 500 & 1500 ppm. Increased incidence of hepatocellular adenomas, carcinomas, and combined adenomas/ carcinomas at HDT	CNQ
Fenbuconazole PC Code: 129011 Tox. Chem. # 723Q		Sprague-Dawley rat, 0, 8, 80, 800, 1600 ppm. Thyroid follicular cell adenomas and/or carcinomas in male rats in two studies.	CQ




Figure 1. Proposed Metabolic Pathway of Difenconazole [CGA 169374] in Rats.